Navigation Links
In Pretreated Advanced Renal Cell Carcinoma, Thought Leaders' Opinions and Clinical Data Indicate that Tivopath Has Efficacy and Tolerability Advantages Over Currently Used Therapies

BURLINGTON, Mass., March 26, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European oncologists agree that a therapy's effect on overall survival and disease progression are the attributes that most influences their decisions regarding prescribing in advanced renal cell carcinoma. Clinical data and the opinions of interviewed thought leaders indicate that Aveo Oncology/Astellas Pharma/Kyowa Hakko Kirin's Tivopath has advantages over currently used therapies on disease progression.

(Logo: )

According to the DecisionBase 2013 report entitled A Promising Immunotherapy Is on the Horizon. What Attributes Does It Need to Trump the Angiogenesis and mTOR Inhibitors?, surveyed U.S. oncologists indicate that they would prescribe Tivopath to 30 percent of their pretreated advanced renal cell carcinoma patients. However, owing to its Phase III clinical trial design and delay in reaching the already crowded market behind Pfizer's Inlyta, Decision Resources forecasts that Tivopath will earn a more modest 11 percent patient share in the U.S. pretreated advanced renal cell carcinoma market by 2021.

The report also finds that surveyed oncologists and managed care organization (MCO) pharmacy directors indicate that improved overall survival and progression-free survival are the greatest unmet needs in pretreated advanced renal cell carcinoma. Interviewed thought leaders are optimistic that Bristol-Myers Squibb's nivolumab has the potential to improve overall survival and at least in part address this unmet need.

"The MCO pharmacy directors we surveyed are particularly receptive to new pretreated advanced renal cell carcinoma therapies that offer improvements in median overall survival over currently available therapies," said Decision Resources Analyst Samuel Mentzer . "While some emerging therapies, such as nivolumab, hold promise, we do not expect any will match the clinical improvement over current therapies that surveyed U.S. payers indicated would be necessary for widespread inclusion on MCO formularies."

About Decision Resources
Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardium Exhibiting Its New FDA-Cleared Excellagen® At The 2012 Spring Symposium Of Advanced Wound Care
2. VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer
3. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
4. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
5. Endocrinology Market to 2018 - Advanced Injection Devices for Growth Hormone and Somatostatin will Improve Ease of Use for Patients
6. Reduction of Chemotherapy and PET-Guided Radiotherapy in Advanced-Stage Hodgkin Lymphoma: the GHSG HD15 Trial
7. Abbott Presents Results of Clinical Studies Evaluating Its Investigational Treatment for Advanced Parkinsons Disease
8. PeriGen, Inc. Introduces New, Advanced Perinatal System at National Perinatal Nursing Convention
9. Advanced Radiotherapy Techniques Explored at Educational Events in India
10. Biosimilars in Emerging Economies - Advanced Recombinant Technology Platforms and Low Cost Manufacturing Put India and China at a Strategic Advantage in Biosimilar Production
11. Health Diagnostic Laboratory, Inc. (HDL, Inc.) Brings Advanced Testing to Capitol Hill, Discusses Health Care Cost Savings and Quality Improvement Potential
Post Your Comments:
(Date:11/26/2015)... 26, 2015 --> ... approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... found that immunotherapy can be efficiently combined with photodynamic ...
(Date:11/26/2015)... SAN FRANCISCO , November 26, 2015 ... 1.82 billion by 2022, according to a new report by ... as Chronic Kidney Disease (CKD) which demands kidney transplantation is ... convenient and cost effective substitute for organ transplantation. --> ... 1.82 billion by 2022, according to a new report by ...
(Date:11/26/2015)... November 26, 2015 ... the "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Country Segment Forecasts, ... their offering. --> ) ... "2016 Future Horizons and Growth Strategies in ...
Breaking Medicine Technology:
(Date:11/27/2015)... Los Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... new study carried out by the University of Toronto and the University of British ... number of hospitalizations for head injuries. The article explains that part of the reason ...
(Date:11/27/2015)... ... 2015 , ... "When I was traveling, I was very ... "Many people catch diseases simply from sitting on such dirty toilet seats. I ... germs." , He developed the patent-pending QUDRATECS to eliminate the need to sit ...
(Date:11/27/2015)... ... 27, 2015 , ... Consistent with the Radiology Business ... Better Radiology Marketing Programs meeting will showcase some of the best 2015 ... Caesars Palace in Las Vegas with a pre-conference session on a collaborative approach ...
(Date:11/27/2015)... , ... November 27, 2015 , ... CBD College ... of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. ... accredited colleges, as only one of twelve colleges and universities in the state of ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point ... come together on Thanksgiving Day to share the things that they are most ... Serenity Point YouTube channel, patients displayed what they wrote on index cards, describing ...
Breaking Medicine News(10 mins):